Eyes on New Product Development

Wechsler J. Will price controls limit drug development? The debate heats up 2021 [updated 2 September 2021; cited 2 September 2021]. 2 September 2021: https://www.appliedclinicaltrialsonline.com/view/will-price-controls-limit-drug-development-the-debate-heats-up- (accessed November 16, 2021).

Anonymous. Genus Medical Technologies LLC Versus Food and Drug Administration; Request for Information and Comments. Fed. Reg. 86:43553–43555, 2021.

Lauck K.C. , Nguyen Q.D. , Grabell D.A. , DarConte M.D. , and Hebert A.A. Association between industry funding and academic productivity among dermatology faculty. J. Am. Acad. Dermatol. 85:733–735, 2021.

Butcher L. A glioblastoma drug is abruptly withdrawn from Medicare that is not good for research trials, neuro-oncologists say. Neurol. Today. 21:10–11, 2021.

Inada M. In Aging Japan, Under 75 Is the New ‘Pre-Old.’ 24 September 2021. Wall St. J., 2021.

Alexander G.C. , Knopman D.S. , Emerson S ,S., et al. Revisiting FDA approval of aducanumab. N. Engl. J. Med. 385:769–771, 2021.

Salloway S. , and Cummings J. Aducanumab, amyloid lowering, and slowing of Alzheimer disease. Neurology. 97:543–544, 2021.

Knopman D.S. , and Perlmutter J.S. Prescribing aducanumab in the face of meager efficacy and real risks. Neurology. 97:545–547, 2021.

Hershey L.A. , and Tarawneh R. Clinical efficacy, drug safety, and surrogate endpoints: has aducanumab met all of its expectations?. Neurology. 97:517–518, 2021.

Steinbrook R. The accelerated approval of aducanumab for treatment of patients with Alzheimer disease. JAMA Intern. Med. 181:1281, 2021.

Dunn B. , Stein P. , and Cavazzoni P. Approval of aducanumab for Alzheimer disease-the FDA's perspective. JAMA Intern. Med. 181:1276–1278, 2021.

Dunn B. , Stein P. , Temple R. , and Cavazzoni P. An appropriate use of accelerated approval—aducanumab for Alzheimer's disease. N. Engl. J. Med. 385:856–857, 2021.